847 Views | 695 Downloads
Sidney H VanNess: svannes@emory.edu; Michael J Owens: mowens@emory.edu; Clinton D Kilts: sdpcdk@emory.edu
SHV performed all molecular biology, radioligand binding experiments, immunoassays, statistical analysis and drafted the manuscript.
MJO participated in the design of the pharmacological aspects of the study, provided supervision of radioligand binding experiments, and aided in the revision of the manuscript.
CDK participated in the overall design and coordination of the study and aided in the drafting of the manuscript.
All authors read and approved the final manuscript.
The authors would like to acknowledge Dr. Marc Caron for generously supplying the DAT1 starting material, Dr. Allan Levey and Mr. Craig Heilman for assistance with DAT western blots, Dr. Michael Kuhar for advice, and Elyse Katz and Dina Ghoneim for technical assistance.
This work was supported by the National Institute of Mental Health (R21 MH067939) and by the National Institute on Drug Abuse (T32 DA015040).
© 2005 VanNess et al; licensee BioMed Central Ltd.